Hidde C. G. Overtoom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hidde C. G. Overtoom has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Bas P. L. Wijnhoven
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
2 shared publications - Ben M. Eyck
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
2 shared publications - Suzanne Sarah Gisbertz
Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands
2 shared publications - Barbara Seeliger
Institute of Image-Guided Surgery, IHU Strasbourg, Strasbourg, France
1 shared publication - Berend Jan van der Wilk
Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam 3015GD, Netherlands
1 shared publication - Bo Jan Noordman
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3622
Development of an Environmental Impact Calculator for Minimally Invasive Cholecystectomy: Protocol and Methodological Framework of the ECOMIS Project
One of the greatest threats to public health in the 21st century is anthropogenic climate change. Healthcare services worldwide account for 4.9% of global CO2 emissions, with operating rooms being the most resource-intensive areas of the hospital. The need for environmentally sustainable change is a priority. Reliable quantitative data on emissions remain limited, which may hinder informed decision-making on surgical sustainability. The aim of this study is to develop and validate an easily accessible and user-friendly calculator to quantitatively estimate procedure-related carbon dioxide equivalent (CO2-eq) emissions of minimally invasive cholecystectomy across a range of countries, hospital volumes, and healthcare settings. The ECOMIS project follows a multiphase, stepwise design. The present study will focus on minimally invasive cholecystectomies. The calculator variables will be selected based on a systematic literature review of factors influencing CO2-eq emissions, with life cycle assessment (LCA) considered an established and comprehensive methodology for assessing CO2-eq emissions. The project will generate a comprehensive quantitative overview of the environmental impact associated with key variables involved in minimally invasive surgery. This tool has the potential to facilitate tailor-made and evidence-based decision-making and promote more sustainable surgical practices.
- 26 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3622
Open AccessDevelopment of an Environmental Impact Calculator for Minimally Invasive Cholecystectomy: Protocol and Methodological Framework of the ECOMIS Project
One of the greatest threats to public health in the 21st century is anthropogenic climate change. Healthcare services worldwide account for 4.9% of global CO2 emissions, with operating rooms being the most resource-intensive areas of the hospital. The need for environmentally sustainable change is a priority. Reliable quantitative data on emissions remain limited, which may hinder informed decision-making on surgical sustainability. The aim of this study is to develop and validate an easily accessible and user-friendly calculator to quantitatively estimate procedure-related carbon dioxide equivalent (CO2-eq) emissions of minimally invasive cholecystectomy across a range of countries, hospital volumes, and healthcare settings. The ECOMIS project follows a multiphase, stepwise design. The present study will focus on minimally invasive cholecystectomies. The calculator variables will be selected based on a systematic literature review of factors influencing CO2-eq emissions, with life cycle assessment (LCA) considered an established and comprehensive methodology for assessing CO2-eq emissions. The project will generate a comprehensive quantitative overview of the environmental impact associated with key variables involved in minimally invasive surgery. This tool has the potential to facilitate tailor-made and evidence-based decision-making and promote more sustainable surgical practices.
- 2 August 2026
- Published by Springer Nature
- p. 415-427
European Experiences
- Open Access
- 17 July 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (5) , 1404-1418
Multidisciplinary Treatment for Esophagogastric Junction Cancer From a Dutch Perspective
Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ cancer in the Netherlands. Perioperative treatment strategies have evolved toward intensified systemic therapy, with perioperative chemotherapy, particularly the FLOT regimen. The preferred approach for surgical treatment of EGJ cancer remains debated, however, minimally invasive transthoracic techniques are increasingly adopted and have led to superior radicality and decreased morbidity. Centralization of care with specialized multidisciplinary teams has been consistently associated with improved surgical quality and survival in the Netherlands, as confirmed by the registry‐based nationwide quality control.
- 17 July 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (5) , 1404-1418
Open AccessMultidisciplinary Treatment for Esophagogastric Junction Cancer From a Dutch Perspective
Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ cancer in the Netherlands. Perioperative treatment strategies have evolved toward intensified systemic therapy, with perioperative chemotherapy, particularly the FLOT regimen. The preferred approach for surgical treatment of EGJ cancer remains debated, however, minimally invasive transthoracic techniques are increasingly adopted and have led to superior radicality and decreased morbidity. Centralization of care with specialized multidisciplinary teams has been consistently associated with improved surgical quality and survival in the Netherlands, as confirmed by the registry‐based nationwide quality control.
- Open Access
- 13 August 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 283 (2) , 268-276
Prolonged Time to Surgery in Patients With Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Objective: To investigate whether prolonged time to surgery negatively affects survival, pathologic outcome, or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer. Background: Historically, the standard time to surgery (TTS) has been 6 to 8 weeks after completion of nCRT. The effect of prolonged TTS is gaining interest, with contradicting results on survival and surgical morbidity. It can be hypothesized that, in patients with residual disease 6 weeks after completion of nCRT, prolonged TTS might be associated with worse survival and higher morbidity. Methods: Patients with locally advanced esophageal cancer who had biopsy-proven residual disease 6 weeks after nCRT and underwent surgery, were categorized according to interval to surgery (TTS>12w vs TTS≤12w). The primary outcome of this study was overall survival. Secondary outcomes were disease-free survival, surgical outcomes, pathologic outcomes, and postoperative complications. Multivariable Cox regression was used for comparing survival and logistic regression for other outcomes, adjusted for the confounders age, cT, cN, Charlson comorbidity index, weight loss during nCRT, and WHO performance score after completion of nCRT. Results: Forty patients were included for TTS>12w and 127 for TTS≤12w. TTS>12w was associated with better overall survival [adjusted hazard ratio (aHR) 0.46, 95% CI: 0.24–0.90], and disease-free survival (aHR 0.48, 95% CI: 0.24–0.94), but also with more postoperative respiratory complications (aOR 3.66, 95% CI: 1.52–9.59). Other outcomes were comparable between both groups. Conclusions: Prolonged TTS in patients with histologically proven residual disease after completion of nCRT for esophageal cancer did not have a negative effect on overall and disease-free survival, but patients did have a higher risk for postoperative respiratory complications.
- 13 August 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 283 (2) , 268-276
Open AccessProlonged Time to Surgery in Patients With Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Objective: To investigate whether prolonged time to surgery negatively affects survival, pathologic outcome, or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer. Background: Historically, the standard time to surgery (TTS) has been 6 to 8 weeks after completion of nCRT. The effect of prolonged TTS is gaining interest, with contradicting results on survival and surgical morbidity. It can be hypothesized that, in patients with residual disease 6 weeks after completion of nCRT, prolonged TTS might be associated with worse survival and higher morbidity. Methods: Patients with locally advanced esophageal cancer who had biopsy-proven residual disease 6 weeks after nCRT and underwent surgery, were categorized according to interval to surgery (TTS>12w vs TTS≤12w). The primary outcome of this study was overall survival. Secondary outcomes were disease-free survival, surgical outcomes, pathologic outcomes, and postoperative complications. Multivariable Cox regression was used for comparing survival and logistic regression for other outcomes, adjusted for the confounders age, cT, cN, Charlson comorbidity index, weight loss during nCRT, and WHO performance score after completion of nCRT. Results: Forty patients were included for TTS>12w and 127 for TTS≤12w. TTS>12w was associated with better overall survival [adjusted hazard ratio (aHR) 0.46, 95% CI: 0.24–0.90], and disease-free survival (aHR 0.48, 95% CI: 0.24–0.94), but also with more postoperative respiratory complications (aOR 3.66, 95% CI: 1.52–9.59). Other outcomes were comparable between both groups. Conclusions: Prolonged TTS in patients with histologically proven residual disease after completion of nCRT for esophageal cancer did not have a negative effect on overall and disease-free survival, but patients did have a higher risk for postoperative respiratory complications.
- 3 May 2024
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (5)
Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis
Locally advanced oesophageal squamous cell carcinoma can be treated with neoadjuvant chemoradiotherapy or chemotherapy followed by oesophagectomy. Discrepancies in pathological response rates have been reported between studies from Eastern versus Western countries. The aim of this study was to compare the pathological response to neoadjuvant chemoradiotherapy in Eastern versus Western countries. Databases were searched until November 2022 for studies reporting pCR rates after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma. Multi-level meta-analyses were performed to pool pCR rates separately for cohorts from studies performed in centres in the Sinosphere (East) or in Europe and the Anglosphere (West). For neoadjuvant chemoradiotherapy, 51 Eastern cohorts (5636 patients) and 20 Western cohorts (3039 patients) were included. Studies from Eastern countries included more men, younger patients, more proximal tumours, and more cT4 and cN+ disease. Patients in the West were more often treated with high-dose radiotherapy, whereas patients in the East were more often treated with a platinum + fluoropyrimidine regimen. The pooled pCR rate after neoadjuvant chemoradiotherapy was 31.7% (95% c.i. 29.5% to 34.1%) in Eastern cohorts versus 40.4% (95% c.i. 35.0% to 45.9%) in Western cohorts (fixed-effect P = 0.003). For cohorts with similar cTNM stages, pooled pCR rates for the East and the West were 32.5% and 41.9% respectively (fixed-effect P = 0.003). The pathological response to neoadjuvant chemoradiotherapy is less favourable in patients treated in Eastern countries compared with Western countries. Despite efforts to investigate accounting factors, the discrepancy in pCR rate cannot be entirely explained by differences in patient, tumour, or treatment characteristics.
- 3 May 2024
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (5)
Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis
Locally advanced oesophageal squamous cell carcinoma can be treated with neoadjuvant chemoradiotherapy or chemotherapy followed by oesophagectomy. Discrepancies in pathological response rates have been reported between studies from Eastern versus Western countries. The aim of this study was to compare the pathological response to neoadjuvant chemoradiotherapy in Eastern versus Western countries. Databases were searched until November 2022 for studies reporting pCR rates after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma. Multi-level meta-analyses were performed to pool pCR rates separately for cohorts from studies performed in centres in the Sinosphere (East) or in Europe and the Anglosphere (West). For neoadjuvant chemoradiotherapy, 51 Eastern cohorts (5636 patients) and 20 Western cohorts (3039 patients) were included. Studies from Eastern countries included more men, younger patients, more proximal tumours, and more cT4 and cN+ disease. Patients in the West were more often treated with high-dose radiotherapy, whereas patients in the East were more often treated with a platinum + fluoropyrimidine regimen. The pooled pCR rate after neoadjuvant chemoradiotherapy was 31.7% (95% c.i. 29.5% to 34.1%) in Eastern cohorts versus 40.4% (95% c.i. 35.0% to 45.9%) in Western cohorts (fixed-effect P = 0.003). For cohorts with similar cTNM stages, pooled pCR rates for the East and the West were 32.5% and 41.9% respectively (fixed-effect P = 0.003). The pathological response to neoadjuvant chemoradiotherapy is less favourable in patients treated in Eastern countries compared with Western countries. Despite efforts to investigate accounting factors, the discrepancy in pCR rate cannot be entirely explained by differences in patient, tumour, or treatment characteristics.